NeuBase Therapeutics Inc. (NBSE)
$0.38
$0.00 (0.00%)As on 24-May-2024 09:30EDT
Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-8 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-6.9
-
Face value
--
-
Shares outstanding
3,751,590
10 Years Aggregate
CFO
$-124.95 Mln
EBITDA
$-181.13 Mln
Net Profit
$-197.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NeuBase Therapeutics (NBSE)
| -48.9 | -10.2 | -46.9 | -90.7 | -84.6 | -63.5 | -59.3 |
|
BSE Sensex*
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
NeuBase Therapeutics (NBSE)
| -80.5 | -93.2 | -59.8 | -2.9 | 318.6 | -95.3 | 24.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NeuBase Therapeutics (NBSE)
|
0.4 | 1.4 | 0.0 | -14.3 | -- | -121.4 | -- | 0.2 |
| 0.0 | 0.0 | -- | -- | -- | -- | -- | 0.0 | |
| 1.5 | 5.2 | 3.6 | 30.3 | -1,439.5 | 31.6 | 0.2 | 0.6 |
Shareholding Pattern
View DetailsAbout NeuBase Therapeutics (NBSE)
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense... oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Read more
-
Interim CEO, CFO & Secretary
Mr. Todd P. Branning
-
Interim CEO, CFO & Secretary
Mr. Todd P. Branning
-
Headquarters
Pittsburgh, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for NeuBase Therapeutics (NBSE)
What is the current share price of NeuBase Therapeutics Inc (NBSE) Today?
The share price of NeuBase Therapeutics Inc (NBSE) is $0.38 (NASDAQ) as of 24-May-2024 09:30 EDT. NeuBase Therapeutics Inc (NBSE) has given a return of -84.63% in the last 3 years.
What is the current PB & PE ratio of NeuBase Therapeutics Inc (NBSE)?
Since, TTM earnings of NeuBase Therapeutics Inc (NBSE) is negative, P/E ratio is not available.
The P/B ratio of NeuBase Therapeutics Inc (NBSE) is 0.18 times as on 18-Jun-2024, a 96 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.02
|
0.03
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of NeuBase Therapeutics Inc (NBSE)?
The 52-week high and low of NeuBase Therapeutics Inc (NBSE) are Rs -- and Rs -- as of 07-Jun-2026.
What is the market cap of NeuBase Therapeutics Inc (NBSE)?
NeuBase Therapeutics Inc (NBSE) has a market capitalisation of $ 1 Mln as on 18-Jun-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in NeuBase Therapeutics Inc (NBSE)?
Before investing in NeuBase Therapeutics Inc (NBSE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.